BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $749,251 | +157.8% | 28,413 | -25.5% | 0.03% | +64.7% |
| Q4 2022 | $290,596 | +56.2% | 38,136 | +103.8% | 0.02% | +41.7% |
| Q3 2022 | $186,000 | -72.5% | 18,708 | -74.9% | 0.01% | -52.0% |
| Q2 2022 | $676,000 | +327.8% | 74,400 | +378.1% | 0.02% | +316.7% |
| Q1 2022 | $158,000 | -79.7% | 15,560 | -66.7% | 0.01% | -82.9% |
| Q4 2021 | $779,000 | +215.4% | 46,695 | +785.9% | 0.04% | +150.0% |
| Q3 2021 | $247,000 | – | 5,271 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |